For instance, in individuals with depression who exhibited elevated inflammatory markers—particularly CRP and tumor necrosis factor-alpha (TNF-α)—treatment with infliximab, a TNF-α antagonist, led to improvements in depressive symptoms14. This evidence concerns the gene TNF and depressive symptom measurement.